- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00389207
Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.
Primary purpose of this study is to compare the efficacy and safety of two different nevirapine (Viramune) dosing regimens (once daily (QD) and twice daily (BID) application) and of atazanavir/ritonavir (Reyataz/Norvir), all on an emtricitabine/tenofovir disoproxil fumarate (DF) (Truvada) background. Patients will receive either nevirapine (NVP) 200 mg twice daily, or NVP 400 mg once daily , or ritonavir-boosted atazanavir (ATZ/r), all in combination with emtricitabine (FTC) and tenofovir DF (TDF).
All patients receiving NVP will start at 200 mg once daily for 2 weeks, because it has been demonstrated that this lead-in dosing regimen reduces the frequency of NVP-induced rash. At Visit 3 (Week 2), patients increase the NVP dose to either 200 mg twice daily or to 400 mg once daily. Patients receiving ATZ/r will be treated with ATZ 300 mg once daily, boosted by 100 mg ritonavir (RTV) once daily. Background antiretroviral therapy for all patients consists of one tablet of Truvada. Treatment duration is 48 weeks (primary endpoint) with an extension to 144 weeks. Patients may also participate in the metabolic sub-study, comparing NVP and ATZ/r for signs and symptoms of lipodystrophy and serum lipid/glycaemic abnormalities.
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Berlin, 독일
- 1100.1470.49001 Boehringer Ingelheim Investigational Site
-
Berlin, 독일
- 1100.1470.49002 Boehringer Ingelheim Investigational Site
-
Bochum, 독일
- 1100.1470.49003 Boehringer Ingelheim Investigational Site
-
Bonn, 독일
- 1100.1470.49018 Boehringer Ingelheim Investigational Site
-
Düsseldorf, 독일
- 1100.1470.49014 Boehringer Ingelheim Investigational Site
-
Erlangen, 독일
- 1100.1470.49008 Boehringer Ingelheim Investigational Site
-
Frankfurt, 독일
- 1100.1470.49035 Boehringer Ingelheim Investigational Site
-
Frankfurt am Main, 독일
- 1100.1470.49036 Boehringer Ingelheim Investigational Site
-
Freiburg/Breisgau, 독일
- 1100.1470.49033 Boehringer Ingelheim Investigational Site
-
Hamburg, 독일
- 1100.1470.49016 Boehringer Ingelheim Investigational Site
-
Hamburg, 독일
- 1100.1470.49031 Boehringer Ingelheim Investigational Site
-
Hamburg, 독일
- 1100.1470.49037 Boehringer Ingelheim Investigational Site
-
Hannover, 독일
- 1100.1470.49020 Boehringer Ingelheim Investigational Site
-
Magdeburg, 독일
- 1100.1470.49038 Boehringer Ingelheim Investigational Site
-
München, 독일
- 1100.1470.49034 Boehringer Ingelheim Investigational Site
-
Ulm, 독일
- 1100.1470.49000 Boehringer Ingelheim Investigational Site
-
Würzburg, 독일
- 1100.1470.49032 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bucharest, 루마니아
- 1100.1470.40001 Boehringer Ingelheim Investigational Site
-
Bucharest, 루마니아
- 1100.1470.40002 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aguascalientes, 멕시코
- 1100.1470.55006 Boehringer Ingelheim Investigational Site
-
Col Obregón, 멕시코
- 1100.1470.55004 Boehringer Ingelheim Investigational Site
-
Col. Los Filtros, San Luis Potosí, 멕시코
- 1100.1470.55008 Boehringer Ingelheim Investigational Site
-
Col. Toriello Guerra, 멕시코
- 1100.1470.55001 Boehringer Ingelheim Investigational Site
-
Guadalajara Jal., 멕시코
- 1100.1470.55007 Boehringer Ingelheim Investigational Site
-
Tlalpan-México D,F, 멕시코
- 1100.1470.55003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bern, 스위스
- 1100.1470.41004 Boehringer Ingelheim Investigational Site
-
Lugano, 스위스
- 1100.1470.41001 Boehringer Ingelheim Investigational Site
-
St. Gallen, 스위스
- 1100.1470.41003 Boehringer Ingelheim Investigational Site
-
Zürich, 스위스
- 1100.1470.41002 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Alcalá de Henares (Madrid), 스페인
- 1100.1470.34013 Boehringer Ingelheim Investigational Site
-
Badalona, 스페인
- 1100.1470.34008 Boehringer Ingelheim Investigational Site
-
Barcelona, 스페인
- 1100.1470.34002 Boehringer Ingelheim Investigational Site
-
Barcelona, 스페인
- 1100.1470.34003 Boehringer Ingelheim Investigational Site
-
L'Hospitalet de Llobregat, 스페인
- 1100.1470.34009 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1100.1470.34010 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1100.1470.34012 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1100.1470.34014 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1100.1470.34015 Boehringer Ingelheim Investigational Site
-
Malaga, 스페인
- 1100.1470.34019 Boehringer Ingelheim Investigational Site
-
Sabadell (Barcelona), 스페인
- 1100.1470.34007 Boehringer Ingelheim Investigational Site
-
San Sebastian, 스페인
- 1100.1470.34004 Boehringer Ingelheim Investigational Site
-
Santa Cruz de Tenerife, 스페인
- 1100.1470.34006 Boehringer Ingelheim Investigational Site
-
Vigo, 스페인
- 1100.1470.34011 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Capital Federal, 아르헨티나
- 1100.1470.54004 Boehringer Ingelheim Investigational Site
-
Córdoba, 아르헨티나
- 1100.1470.54002 Boehringer Ingelheim Investigational Site
-
Mar del Plata, 아르헨티나
- 1100.1470.54003 Boehringer Ingelheim Investigational Site
-
Rosario, 아르헨티나
- 1100.1470.54001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Birmingham, 영국
- 1100.1470.44004 Boehringer Ingelheim Investigational Site
-
London, 영국
- 1100.1470.44001 Boehringer Ingelheim Investigational Site
-
London, 영국
- 1100.1470.44002 Boehringer Ingelheim Investigational Site
-
London, 영국
- 1100.1470.44005 Boehringer Ingelheim Investigational Site
-
London, 영국
- 1100.1470.44006 Boehringer Ingelheim Investigational Site
-
Manchester, 영국
- 1100.1470.44003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bergamo, 이탈리아
- 1100.1470.39001 Boehringer Ingelheim Investigational Site
-
Bologna, 이탈리아
- 1100.1470.39003 Boehringer Ingelheim Investigational Site
-
Como, 이탈리아
- 1100.1470.39012 Ospedale Sant'Anna
-
Ferrara, 이탈리아
- 1100.1470.39006 Boehringer Ingelheim Investigational Site
-
Lecco, 이탈리아
- 1100.1470.39010 Boehringer Ingelheim Investigational Site
-
Torino, 이탈리아
- 1100.1470.39004 Boehringer Ingelheim Investigational Site
-
Torrette Di Ancona, 이탈리아
- 1100.1470.39009 Boehringer Ingelheim Investigational Site
-
Varese, 이탈리아
- 1100.1470.39007 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Cascais, 포르투갈
- 1100.1470.35102 Boehringer Ingelheim Investigational Site
-
Lisboa, 포르투갈
- 1100.1470.35101 Boehringer Ingelheim Investigational Site
-
Porto, 포르투갈
- 1100.1470.35103 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bydgoszcz, 폴란드
- 1100.1470.48003 Boehringer Ingelheim Investigational Site
-
Chorzow, 폴란드
- 1100.1470.48001 Boehringer Ingelheim Investigational Site
-
Szczecin, 폴란드
- 1100.1470.48002 Boehringer Ingelheim Investigational Site
-
Warsaw, 폴란드
- 1100.1470.48004 Boehringer Ingelheim Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
Inclusion Criteria:
- Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
- HIV-1-infected males or females >= 18 years of age with positive serology confirmed by Western blot
- No previous antiretroviral treatment (of more than 7 days)
- Males with CD4+ counts of < 400 cells/mm3 and females with CD4+ counts of < 250 cells/mm3
- NVP- and ATZ/r susceptibility based on HIV-1 genotypic resistance report
- Adequate renal function defined as a calculated creatinine clearance (CLCr) >= 50 ml/min according to the Cockcroft-Gault formula
- Karnofsky score >= 70
- Acceptable medical history, as assessed by the investigator
Exclusion criteria:
Exclusion Criteria:
- Active drug abuse or chronic alcoholism at the investigator's discretion
- Hepatic cirrhosis stage Child-Pugh B or C
Female patients of child-bearing potential who:
- have a positive serum pregnancy test at screening or during the study,
- are breast feeding,
- are planning to become pregnant,
- are not willing to use a barrier method of contraception, or are not willing to use methods of contraception other than ethinyl estradiol containing oral contraceptives
- Laboratory parameters Division of Acquired Immunodeficiency Syndrome (DAIDS) > grade 2 (triglycerides > DAIDS grade 3; total cholesterol no restrictions)
- Active hepatitis B or C disease, defined as HBsAg-positive or Hepatitis C-Virus-Ribo Nucleic Acid (HCV-RNA)- positive with Aspartate Transaminase/Alanine Transaminase (AST/ALT) > 2.5x Upper Limit of Normal (ULN) (DAIDS grade 1)
- Hypersensitivity to any ingredients of the test products
- Have therapy with nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cisplatin, pentamidine, tacrolimus, cyclosporine) or potential competitors of renal excretion (e.g., cidofovir, acyclovir, valacyclovir, ganciclovir, valganciclovir, probenecid, high-dose non-steroidal anti-inflammatory drugs (i.e., ibuprofen)) within 3 months prior to study screening or are expected to receive these during the study
- Patients who are receiving other concomitant treatments which are not permitted
- Use of other investigational medications within 30 days before study entry or during the trial
- Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2, chronic treatment with prednisone)
- Patients with Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's Sarcoma (KS), and/or any lymphoma
- Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit
- Patients who are receiving systemic treatment for malignant disease
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: NVP bid
nevirapine (NVP) 200 mg BID in combination with emtricitabine (FTC) and tenofovir DF (TDF)
|
nevirapine twice daily
|
실험적: NVP qd
nevirapine (NVP) 400 mg QD in combination with emtricitabine (FTC) and tenofovir DF (TDF)
|
nevirapine once daily
|
활성 비교기: ATZ/r
ritonavir-boosted atazanavir in combination with emtricitabine (FTC) and tenofovir DF (TDF)
|
atazanavir once daily
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Treatment Response at Week 48
기간: From baseline to Week 48
|
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 48.
|
From baseline to Week 48
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Treatment Response at Week 48 (TLOVR Algorithm)
기간: From baseline to Week 48
|
Treatment response is defined as a VL <50 copies/mL measured at two consecutive visits up to Week 48 and without subsequent rebound or change of ARV therapy up to Week 48, based on time to loss of virologic response (TLOVR) algorithm, as a sensitivity analysis for the primary analysis.
|
From baseline to Week 48
|
Proportion of Patients With VL < 50 Copies/ml
기간: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
|
VL <50 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) for the patient
|
From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
|
Proportion of Patients With VL < 400 Copies/ml
기간: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
|
VL <400 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT)
|
From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
|
Change in CD4+ Count From Baseline
기간: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
|
Change in CD4+ cell count from baseline among patients on treatment at each visit, with the final visit at Week 144 or EOT
|
From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
|
Change in Framingham Score From Baseline
기간: From baseline to Weeks 48, 96 and 144/EOT
|
Change in the estimated risk of cardiovascular disease using the Framingham algorithm from baseline to after 48, 96 and 144 weeks, last observation carried forward (LOCF).
The score is based on age, gender, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol and smoking status.
Scores range from 0 to 21 with higher scores indicating a greater risk.
|
From baseline to Weeks 48, 96 and 144/EOT
|
Change in Mental Health Summary (MHS) Score From Baseline
기간: From baseline to Weeks 48, 96 and 144/EOT
|
Quality of life (QoL) assessment by change in MHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL.
The MHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL.
|
From baseline to Weeks 48, 96 and 144/EOT
|
Change in Physical Health Summary (PHS) Score From Baseline
기간: From baseline to Weeks 48, 96 and 144/EOT
|
QoL assessment by change in PHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the MOS-HIV, a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL.
The PHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL.
|
From baseline to Weeks 48, 96 and 144/EOT
|
Number of Patients Hospitalized
기간: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT
|
Cost effectiveness assessment by number of patients hospitalized
|
From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT
|
Non-scheduled Physician Visits
기간: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT
|
Cost effectiveness assessment by number of patients with non-scheduled physician visits
|
From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT
|
Genotypic Resistance Associated With Virologic Failure
기간: From baseline to Week 48
|
Number of treatment-emergent drug-associated substitutions in patients with virological failure up to Week 48.
The total number of genotypic mutations in those patients who were virologic failures is given, not the number of patients with mutations.
|
From baseline to Week 48
|
Treatment-emergent AIDS-defining Illness
기간: From baseline to Week 144
|
Treatment-emergent AIDS-defining illness (tr.-emerg.
AIDS-def.illness)
including worsening during treatment
|
From baseline to Week 144
|
Treatment-emergent AIDS-defining Illness Leading to Death
기간: From baseline to Week 144
|
Patients with an AIDS-defining illness leading to death broken out by treatment.
Statistical analysis shows time to death from AIDS-defining illness.
|
From baseline to Week 144
|
Lipodystrophy
기간: From baseline to Week 144
|
Number of patients with AE lipodystrophy
|
From baseline to Week 144
|
Serum Lipid Abnormalities
기간: From baseline to Week 144
|
Number of patients with AE elevated serum lipids (i.e.
hypercholesterolaemia)
|
From baseline to Week 144
|
Glycaemic Abnormalities
기간: From baseline to Week 144
|
Number of patients with AE elevated serum glucose
|
From baseline to Week 144
|
Treatment Response at Week 96
기간: From baseline to Week 96
|
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 96 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 96.
|
From baseline to Week 96
|
Treatment Response at Week 144
기간: From baseline to Week 144
|
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 144 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 144.
|
From baseline to Week 144
|
Proportion of Patients With Virological Rebound With VL >=50 Copies/mL After CVR (Confirmed Virological Response) at Week 24, 48, 96, 144
기간: at Week 24, 48, 96, 144
|
The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL)
|
at Week 24, 48, 96, 144
|
Proportion of Patients With Virological Rebound With VL >=400 Copies/mL After CVR at Week 24, 48, 96, 144
기간: at Week 24, 48, 96, 144
|
The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL)
|
at Week 24, 48, 96, 144
|
Proportion of Patients With Virologic Failure at Week 48, 96, 144
기간: at Week 48, 96, 144
|
at Week 48, 96, 144
|
|
Time to Treatment Response (First Confirmed VL<50 Copies/mL)
기간: baseline to week 144
|
Time to treatment response was defined as the time from start of treatment until the first measurement of the first confirmed virological response
|
baseline to week 144
|
Time to Loss of Virologic Response (Rebound)
기간: Baseline to week 144
|
Time to loss of virologic response (TLOVR) was defined as the time from start of treatment to the first measurement showing VL ≥ 50 copies/mL in the first virologic rebound, after having a confirmed virological response.
|
Baseline to week 144
|
Time to Treatment Failure
기간: baseline to week 144
|
Treatment failure is defined as the occurrence of the first of at least one of the following events: early discontinuation of trial drug, change in ARV therapy, failure to achieve an HIV RNA count < 50 copies/mL up to Visit 10 (week 48) or loss of virologic response
|
baseline to week 144
|
Change in the Calculated Glomerular Filtration Rate (GFR) at Week 48, 96 and 144
기간: From baseline to Week 48, 96, 144
|
Calculations based on the MDRD algorithm.
|
From baseline to Week 48, 96, 144
|
Proportion of Patients With >= DAIDS Grade 2 Laboratory Abnormalities
기간: week 148
|
week 148
|
|
Proportion of Patients Reporting Rash of Any Severity
기간: week 148
|
Proportion of Patients reporting rash of any severity
|
week 148
|
Proportion of Patients Reporting Hepatic Events of Any Severity
기간: week 148
|
Proportion of Patients reporting hepatic events of any severity
|
week 148
|
Proportion of Patients Reporting CNS (Central Nervous System) Side Effects of Any Severity
기간: week 148
|
Proportion of Patients reporting CNS (central nervous system) side effects of any severity
|
week 148
|
Change of Cholesterol Values From Baseline to Week 48, 96, 144
기간: baseline to week 48, 96, 144
|
Changes frombaseline in total cholesterol, LDL-cholesterol(LDL-c) and HDL
|
baseline to week 48, 96, 144
|
Changes of Apolipoprotein Values From Baseline to Week 48, 96, 144
기간: baseline to week 48, 96, 144
|
Changes frombaseline apolipoprotein A1 & B
|
baseline to week 48, 96, 144
|
Change of hsCRP From Baseline to Week 48, 96, 144
기간: baseline to week 48, 96, 144
|
Change of hsCRP from baseline to week 48, 96, 144
|
baseline to week 48, 96, 144
|
Change of Total Triglycerides From Baseline to Week 48, 96, 144
기간: baseline to week 48, 96, 144
|
Change of total triglycerides from baseline to week 48, 96, 144
|
baseline to week 48, 96, 144
|
Change of Total Cholesterol to HDL-cholesterol Ratio From Baseline to Week 48, 96, 144
기간: baseline to week 48, 96, 144
|
Change of Total cholesterol to HDL-cholesterol ratio from baseline to week 48, 96, 144
|
baseline to week 48, 96, 144
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Seclen E, Soriano V, Gonzalez MM, Martin-Carbonero L, Gellermann H, Distel M, Kadus W, Poveda E. Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy. J Infect Dis. 2011 Jul 1;204(1):139-44. doi: 10.1093/infdis/jir218.
- Soriano V, Arasteh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L; ARTEN investigators. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16(3):339-48. doi: 10.3851/IMP1745.
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 1100.1470
- 2005-004330-40 (EudraCT 번호: EudraCT)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
HIV 감염에 대한 임상 시험
-
Hospital Clinic of Barcelona완전한
-
CDC FoundationGilead Sciences알려지지 않은
-
University of WashingtonNational Institute of Mental Health (NIMH)모병
-
University of Minnesota빼는HIV 감염 | HIV/에이즈 | 에이즈 | 보조기구 | 에이즈/HIV 문제 | 에이즈와 감염미국
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS Foundation완전한파트너 HIV 테스트 | 부부 에이즈 상담 | 커플커뮤니케이션 | HIV 발병률카메룬, 도미니카 공화국, 그루지야, 인도
-
Michael HoelscherClinton Health Access Initiative Inc.; Instituto Nacional de Saúde (INS), Ministério da... 그리고 다른 협력자들모집하지 않고 적극적으로HIV, 신생아 HIV 조기 진단(EID), 현장 진료 검사(PoC)모잠비크, 탄자니아
-
Allegheny Singer Research Institute (also known...모집하지 않고 적극적으로
-
Erasmus Medical Center모집하지 않고 적극적으로
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)완전한
-
Erasmus Medical Center모병
nevirapine bid에 대한 임상 시험
-
Haisco Pharmaceutical Group Co., Ltd.완전한
-
Santen Inc.ActualEyes Inc.모집하지 않고 적극적으로Fuchs 내피 각막 이영양증미국, 프랑스, 인도
-
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.아직 모집하지 않음
-
Merck Sharp & Dohme LLC완전한만성 기침캐나다, 체코, 덴마크, 헝가리, 페루, 폴란드, 우크라이나, 영국, 미국, 호주, 중국, 콜롬비아, 독일, 과테말라, 이스라엘, 이탈리아, 말레이시아, 뉴질랜드, 남아프리카, 칠면조
-
Vifor (International) Inc.Labcorp Drug Development Inc빼는
-
Altavant Sciences GmbH완전한폐동맥 고혈압미국, 스페인, 영국, 체코, 세르비아, 캐나다, 폴란드, 이탈리아, 보스니아 헤르체고비나, 오스트리아, 독일, 벨기에, 불가리아, 프랑스, 라트비아, 몰도바 공화국, 우크라이나